Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 3, March, p. 409–414

doi: 10.17219/acem/67051

Publication type: review article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Short stature in genetic syndromes: Selected issues

Izabela Łaczmańska1,D,E, Justyna Kuliczkowska-Płaksej2,D,E, Agnieszka Stembalska1,D,F

1 Department of Genetics, Wroclaw Medical University, Poland

2 Department of Endocrinology, Diabetology and Isotope Therapy, Wroclaw Medical University, Poland


Short stature, which is defined as height below 2 standard deviations of the mean height for the age and sex, is one of the most frequent reasons for medical consultations in children. Short stature may occur due to a constitutional delay in growth, familial short stature or chronic diseases, including many genetic syndromes, metabolic and endocrine disorders. In this article the authors provide a mini-review of the most frequent genetic syndromes associated with short stature that should be taken into account in the differential diagnosis process. Syndromes caused by chromosomal aberrations and gene mutations were divided into 2 main groups: syndromes that are associated with intrauterine growth retardation (IUGR) and those in which IUGR does not occur in the natural history of the patient. The authors described the most important anomalies in each syndrome. Metabolic diseases and skeletal dysplasias were omitted, as they are major separate groups of diseases involving growth delay.

Key words

IUGR, short stature, genetic syndromes

References (35)

  1. Johnston Rohrbasser LB. Genetic testing of the short child. Horm Res Paediatr. 2011;76(3):13–16.
  2. Petriczko E, Horodnicka-Jozwa A, Walczak M. Diagnostic evaluation before growth hormone deficiency recognition (exclusion criteria). Endokrynol Pediatr. 2009;9:13–22.
  3. Siklar Z, Berberoglu M. Syndromic disorders with short stature. J Clin Res Pediatr Endocrinol. 2014;6(1):1–8.
  4. Krakow D, Rimoin DL. The skeletal dysplasias. Genet Med. 2010;12(6):327–341.
  5. Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford). 2011;50(5):v4–12.
  6. Phung OJ, Coleman CI, Baker EL, et al. Recombinant human growth hormone in the treatment of patients with cystic fibrosis. Pediatrics. 2010;26(5):e1211–1226.
  7. Winter-Baraitser Dysmorphology Database (London Medical Data- base) Accessed April 18, 2016.
  8. Kelnar CJ. Growth hormone therapy for syndromic disorders. Clin Endocrinol (Oxf ). 2003;59(1):12–21.
  9. Sangu N, Shimojima K, Shimada S, Ando T, Yamamoto T. Growth patterns of patients with 1p36 deletion syndrome. Congenit Anom (Kyoto). 2014;54(2):82–86.
  10. Gajecka M, Mackay KL, Shaffer LG. Monosomy 1p36 deletion syndrome. Am J Med Genet C Semin Med Genet. 2007;15:145C(4), 346–356.
  11. Keppler-Noreuil KM, Carroll AJ, Finley WH, Rutledge SL. Chromosome 1p terminal deletion: Report of new findings and confirmation of two characteristic phenotypes. J Med Genet. 1995;32(8):619–622.
  12. Battaglia A, Hoyme HE, Dallapiccola B, et al. Further delineation of deletion 1p36 syndrome in 60 patients: A recognizable phenotype and common cause of developmental delay and mental retardation. Pediatrics. 2008;121(2):404–410.
  13. Holder-Espinasse M. 3-M Syndrome. In: Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K. GeneRe- views® [Internet]. Seattle (WA): University of Washington; 1993–2014. Published March 25, 2002. Updated January 26, 2012. Accessed April 18, 2016.
  14. Keller C, Keller KR, Shew SB, Plon SE. Growth deficiency and malnutrition in Bloom syndrome. J Pediatr. 1999;134(4):472–479.
  15. Boyle MI, Jespersgaard C, Brøndum-Nielsen K, Bisgaard AM, Tümer Z. Cornelia de Lange syndrome. Clin Genet. 2015;88(1):1–12.
  16. Nikkel SM, Dauber A, de Munnik S, et al. The phenotype of Floating-Harbor syndrome: Clinical characterization of 52 individuals with mutations in exon 34 of SRCAP. Orphanet J Rare Dis. 2013;8:63.
  17. Iliev DI, Kannenberg K, Weber K, Binder G. IGF-I sensitivity in Silver-Russell syndrome with IGF2/H19 hypomethylation. Growth Horm IGF Res. 2014;24(5):187–191.
  18. Roizen NJ, Patterson D. Down’s syndrome. Lancet. 2003;361(9365):1281–1289.
  19. Myrelid A, Gustafsson J, Ollars B, Annerén G. Growth charts for Down’s syndrome from birth to 18 years of age. Arch Dis Child. 2002;87(2):97–103.
  20. Krefft M, Frydecka D, Adamowski T, Misiak B. From Prader-Willi syndrome to psychosis: Translating parent-of-origin effects into schizophrenia research. Epigenomics. 2014;6(6):677–688.
  21. Gawlik A, Malecka-Tendera E. Transitions in endocrinology: Treatment of Turner’s syndrome during transition. Eur J Endocrinol. 2013;170(2):R57–74.
  22. Pinsker JE. Clinical review: Turner syndrome: Updating the paradigm of clinical care. J Clin Endocrinol Metab. 2012;97(6):E994–1003.
  23. Cody JD, Hale DE, Brkanac Z, Kaye CI, Leach RJ. Growth hormone insufficiency associated with haploinsufficiency at 18q23. Am J Med Genet. 1997;71(4):420–425.
  24. Linnankivi T, Tienari P, Somer M, et al. 18q deletions: Clinical, molecular, and brain MRI findings of 14 individuals. Am J Med Genet A. 2006;140(4):331–339.
  25. Laron Z, Kauli R. Fifty seven years of follow-up of the Israeli cohort of Laron Syndrome patients – from discovery to treatment. Growth Horm IGF Res. 2016;28:53–56. doi: 10.1016/j.ghir.2015.08.004
  26. Goswami S, Ghosh S, Chowdhury S. Growth hormone insensitivity syndrome: A sensitive approach. Indian J Endocrinol Metab. 2012;16(5):817–818.
  27. Laron Z, Lilos P, Klinger B. Growth curves for Laron syndrome. Arch Dis Child. 1993;68(6):768–770.
  28. Ross JL, Kowal K, Quigley CA, et al. The phenotype of short stature homeobox gene (SHOX) deficiency in childhood: Contrasting children with Leri-Weill dyschondrosteosis and Turner syndrome. J Pediatr. 2005;147(4):499–507.
  29. Romano AA, Allanson JE, Dahlgren J, et al. Noonan syndrome: Clinical features, diagnosis, and management guidelines. Pediatrics. 2010;126(4):746–759.
  30. Agarwal P, Philip R, Gutch M, Gupta KK. The other side of Turner’s: Noonan’s syndrome. Indian J Endocrinol Metab. 2013;17(5):794–798.
  31. Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. Lancet. 2013;381(9863):333–42.
  32. Varadinova M, Boyadjieva N. Epigenetic mechanisms: A possible link between autism spectrum disorders and fetal alcohol spectrum disorders. Pharmacol Res. 2015;102:71–80.
  33. Landgraf MN, Nothacker M, Kopp IB, Heinen F. The diagnosis of fetal alcohol syndrome. Dtsch Arztebl Int. 2013;110(42):703–710.
  34. Klug MG, Burd L, Martsolf JT, Ebertowski M. Body mass index in fetal alcohol syndrome. Neurotoxicol Teratol. 2003;25:689–696.
  35. Kanazawa H, Tanaka H, Inoue M, Yamanaka Y, Namba N, Seino Y. Efficacy of growth hormone therapy for patients with skeletal dysplasia. J Bone Miner Metab. 2003;21(5):307–310.